Opinion: Pricing info with new drug approvals: Time for transparency
For years Congress has raised concerns with the way some drugmakers pay to delay generic versions of their branded blockbusters, as well as other patent and evergreening techniques to add to their sales of older products.
These games and other obfuscation tactics have long extended to drug pricing too. Finding information on the price of a new drug, or even better, what someone will actually have to pay out of pocket for that new drug (which is usually not the same as the WAC or list price that’s announced), can be exceedingly difficult to find or understand. Sometimes companies will announce the list price for a new drug, but other times that announcement will come later, or be buried in an SEC filing, or only discoverable publicly in a government database years later.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.